<DOC>
	<DOC>NCT02126917</DOC>
	<brief_summary>To determine the influence of co-ingestion of alcohol on HC-ER.</brief_summary>
	<brief_title>A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)</brief_title>
	<detailed_description>Determine the influence of co-ingestion of alcohol on the safety, pharmacokinetics, and relative bioavailability of HC-ER 50 mg under fasted conditions</detailed_description>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>Males and females, ages 21 to 45. Female, must be of nonchildbearing potential. Nonsmokers for at least 3 months or light smokers (less than 10 packyears). History of moderate consumption of between 721 units of alcohol per week. Weighed at least 65 kg with a BMI ≥19 and ≤35 kg/m2. Were medically healthy with no clinically significant abnormalities. Voluntarily consented to participate in the study. Were prepared to be compliant with the study procedures. Women who were pregnant or breastfeeding. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. History or presence of alcoholism or drug abuse. Hypersensitivity or idiosyncratic reaction to morphine, hydrocodone (Vicodin) or other opioids; naltrexone, naloxone, or other opioid antagonist. History of no alcohol intake (alcoholnaive) or less than moderate alcohol intake. History of alcohol intake exceeding the equivalence of 21 units/week or exceeding the average of 3 drinks per day. Surgery of the gastrointestinal tract which would interfere with absorption of the study drug. Taken hepatic enzyme inducing drugs (e.g., Nizoral, Tagamet) within the previous 3 months. Taken prescription medications within the previous 14 days or over the counter (OTC) medications within the previous 7 days prior to Day 1 Period 1. Sitting blood pressure was less than 110/45 mmHg at screening. On a special diet (except for vegetarians who agree to abide by study diet) during the 28 days prior to the first dose and throughout the study. Significant blood donation or loss within 56 days prior to first dose of HCER. Plasma donation within 7 days prior to first dose of HCER. Hemoglobin value less than 12.0 g/dL. Participated in another clinical trial within 28 days prior to first dose of HCER. Positive urine test for drugs of abuse. Positive test for, or had been treated for hepatitis B, hepatitis C or HIV.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Alcohol</keyword>
	<keyword>Hydrocodone Bitartrate</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>